Urinary Biomarkers in Cancer: A Scoping Review
- 1Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
Abstract
Cancer remains a major global health challenge and a leading cause of mortality worldwide. As incidence continues to rise, early detection remains one of the most effective strategies for improving survival and reducing disease burden. Urine is an attractive source of biomarkers due to its non-invasive collection, ease of repeated sampling, and rich molecular composition. This scoping review evaluates the current landscape of urinary biomarkers for the early detection of cancer and their potential for clinical translation. A detailed literature search was conducted using PubMed, Embase, and Web of Science to identify studies investigating urinary biomarkers for cancer detection. Biomarkers were categorised by analyte class, and diagnostic performance, validation status, and clinical applicability were assessed. Urinary biomarkers demonstrated diagnostic potential across multiple malignancies, including lung, breast, pancreatic, hepatobiliary, colorectal, renal and ovarian cancers, while several urinary assays are already clinically available for bladder and prostate cancers. Promising diagnostic accuracy was reported for multiple biomarker classes, particularly multimarker panels integrating metabolites, proteins, nucleic acids, and epigenetic signatures. However, most studies were exploratory, involving small cohorts, methodological heterogeneity, and limited independent validation. Urinary biomarkers represent a promising and rapidly evolving approach to non-invasive cancer detection. Despite encouraging diagnostic performance, few candidates have progressed to clinical implementation. Large prospective multicentre studies, rigorous validation, and assay standardisation are essential to establish urinary biomarkers as reliable tools for cancer screening, early diagnosis, and risk stratification.
Related
- Safe and unsafe urinary catheter use in long-term care homes: a human factors-informed scoping review protocol
- Biomarkers in ANCA-Associated Vasculitis-Associated Interstitial Lung Disease: A Scoping Review
- Self‐Management Interventions for Lower Urinary Tract Symptoms After Radical Prostatectomy: A Scoping Review of Intervention Components, Outcomes and Research Gaps
- Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer
- The relationship between endometrial cancer and urinary incontinence: systematic review
BibTeX
@article{kurotova2026urinary,
title = {{Urinary Biomarkers in Cancer: A Scoping Review}},
author = {Evelyn Kurotova and Jayni Shah and Lucia Pueyo Valles and Edwina Burke and Ruben Berreby and Yong-Jie Lu and Silvana Debernardi and Tatjana Crnogorac-Jurcevic},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203328},
url = {https://www.mdpi.com/2072-6694/18/20/3328},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Urinary Biomarkers in Cancer: A Scoping Review
AU - Evelyn Kurotova
AU - Jayni Shah
AU - Lucia Pueyo Valles
AU - Edwina Burke
AU - Ruben Berreby
AU - Yong-Jie Lu
AU - Silvana Debernardi
AU - Tatjana Crnogorac-Jurcevic
PY - 2026
DA - 2026/10/15
JO - Cancers
DO - 10.3390/cancers18203328
UR - https://www.mdpi.com/2072-6694/18/20/3328
AB - Cancer remains a major global health challenge and a leading cause of mortality worldwide. As incidence continues to rise, early detection remains one of the most effective strategies for improving survival and reducing disease burden. Urine is an attractive source of biomarkers due to its non-invasive collection, ease of repeated sampling, and rich molecular composition. This scoping review evaluates the current landscape of urinary biomarkers for the early detection of cancer and their potential for clinical translation. A detailed literature search was conducted using PubMed, Embase, and Web of Science to identify studies investigating urinary biomarkers for cancer detection. Biomarkers were categorised by analyte class, and diagnostic performance, validation status, and clinical applicability were assessed. Urinary biomarkers demonstrated diagnostic potential across multiple malignancies, including lung, breast, pancreatic, hepatobiliary, colorectal, renal and ovarian cancers, while several urinary assays are already clinically available for bladder and prostate cancers. Promising diagnostic accuracy was reported for multiple biomarker classes, particularly multimarker panels integrating metabolites, proteins, nucleic acids, and epigenetic signatures. However, most studies were exploratory, involving small cohorts, methodological heterogeneity, and limited independent validation. Urinary biomarkers represent a promising and rapidly evolving approach to non-invasive cancer detection. Despite encouraging diagnostic performance, few candidates have progressed to clinical implementation. Large prospective multicentre studies, rigorous validation, and assay standardisation are essential to establish urinary biomarkers as reliable tools for cancer screening, early diagnosis, and risk stratification.
SN - 2072-6694
ER -